Micro/nanoparticle design and fabrication for pharmaceutical drug preparation and delivery applications

Current Drug Therapy

Volumn 3, Issue 2, 2008, Pages 78-97

  Sahoo, Nanda Gopal ^a   Abbas, Ali ^b   Li, Chang Ming ^a  

^a Nanyang Technological University   (Singapore)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bioavailability; Dissolution; Drug delivery; Microparticles; Nanoparticles; Poorly soluble drugs; Preparation technologies

Indexed keywords

ALBENDAZOLE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; BUDESONIDE; BUPIVACAINE; CARBAMAZEPINE; CEFUROXIME AXETIL; CHITOSAN; CILOSTAZOL; CYCLOSPORIN; CYTOTOXIC AGENT; DEXTRAN; DOXORUBICIN; ETHENZAMIDE; GELATIN; GRISEOFULVIN; INDOMETACIN; KETOPROFEN; NANOCRYSTAL; NANOPARTICLE; NIFEDIPINE; NIMESULIDE; PACLITAXEL; PHENYTOIN; PHOSPHATIDYLCHOLINE; POLYMER; QW 8184; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ANTINEOPLASTIC ACTIVITY; BIOASSAY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG PURIFICATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; HUMAN; LYSOSOME; MELANOMA; MICROEMULSION; NANOMEDICINE; NONHUMAN; OSTEOSARCOMA; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPRAY DRYING; SUSPENSION; WEIGHT REDUCTION;

EID: 54949107365     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488508784221253     Document Type: Review

References (217)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
2. Teicher BA Ed, Anticancer drug delivery guide, Philadelphia, Humana Press 1997.
3. Fernandez AM, Van Derpoorten K, Dasnois L, Lebtahi K, Dubois V, Lobl TZ. N-succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl) doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J Med Chem 2001; 44: 3750-3753.
4. Yalkowsky SH Ed, Techniques of Solubilization of Drugs. New York, Marcel Dekker 1981.
5. Svenson D Ed, Carrier-Based Drug Delivery. ACS, Washington, Dc, 2004; 2-23.
6. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
7. Subramaniam B, Rajewski RA, Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 1997; 86: 885-890.
8. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997; 86: 1-12.
9. Grau MJ, Kayser O, Muller RH. Nanosuspensions of poorly soluble drugs-reproducibility of small scale production. Int J Pharm 2000; 196: 155-157.
10. Merisko-Liverside E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water soluble compounds. Eur J Pharm Sci 2003; 18: 113-120.
11. Rasenack N, Hartenhauer H, Muller BW. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm 2003; 254: 137-145.
12. Lopez-Quintela MA. Synthesis of nanomaterials in microemulsions: formation mechanisms and growth control. Curr Opin Colloid Interface Sci 2003; 8: 137-144.
13. Rogers TL, Overhoff KA, Shah P, et al. Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid-emulsion process. Eur J Pharm Biopharm 2003; 55: 161-172.
14. Hu J, Rogers TL, Brown JN, Young TJ, Johnston KP, Williams RO. Improvement of dissolution rates of poorly water soluble APIs using the novel spray freezing into liquid technology. Pharm Res 2002; 19: 1278-1284.
15. Billon A, Bataille B, Cassanas G, Jacob M. Development of spray-dried acetaminophen microparticles using experimental designs. Int J Pharm 2003; 203: 159-168.
16. Moretti MDL, Gavini E, Juliano C, Pirisino G, Giunchedi P. Spray-dried microspheres containing ketoprofen formulated into capsules and tablets. J Microencapsul 2001; 18: 111-121.
17. Mizoe T, Beppu S, Ozeki T, Okada H. One-step preparation of drug-containing microparticles to enhance the dissolution and absorption of poorly water-soluble drugs using a 4-fluid nozzle spray drier. J Control Release 2007; 120: 205-210.
18. Jung J, Perrut M. Particle design using supercritical fluids: Literature and patent survey. J Super Fluids 2001; 20: 179-219.
19. Shariati A, Peters CJ. Recent developments in particle design using supercritical fluids. Curr Opin Sol St Mater Sci 2003; 7: 371-383.
20. Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water soluble drug: Generation of drug microparticles and drug-polymer dispersions. Int J Pharm 2006; 308: 69-83.
21. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 930-934.
22. Douroumis D, Fahr A. Enhanced dissolution of Oxacarbazepine microcrystals using a static mixer process. Colloid Surf B: Biointerfaces 2007; 59: 208-214.
23. Kim MS, Lee S, Park JS, Woo JS, Hwang SJ. Micronization of cilostazol using supercritical antisolvent (SAS) process: Effect of process parameters. Powder Tech 2007; 177: 64-70.
24. Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations. Eur J Pharm Biopharm 2007, doi: 10.1016/j.ejbp.2007.05.010.
25. Munoz A, Guichard JP, Reginault P. Micronized fenofibrate. Atherosclerosis 1994; 110(Suppl.): S45-S48.
26. Chaumeil JC. Micronization: a method of improving the bioavailability of poorly soluble drugs. Meth Find Exp Clin Pharmacol 1998; 20: 211-215.
27. Parrott EL. In: Swarbrick J, Boylan JC, Eds, Comminution. Encyclopedia of pharmaceutical technology, Marcel Decker Inc, New York. 1990; 3: 101-121.
28. Muller RH. Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm 1998; 160: 229-237.
29. Meng FT, Ma GH, Qiu W, Su ZG. W/O/W double emulsion technique using ethyl acetate as organic solvent: effects of its diffusion rate on the characteristics of microparticles. J Control Release 2003; 91: 407-416.
30. Couvreur P, Blanco-Prieto MJ, Puisieux F, Roques B, Fattal E. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. Adv Drug Del Rev 1997; 28: 85-96.
31. Cortesi R, Menegatti E, Esposito E. Spray-drying production of trypsin-containing microparticles. STP Pharma Sci 2003; 13: 329-334.
32. Huang YC, Yeh MK, Cheng SN, Chiang CH. The characteristics of betamethasone-loaded chitosan microparticles by spray drying method. J Microencapsul 2003; 20: 459-472.
33. Kharb V, Bhatia M, Dureja H, Kaushik D. Nanoparticle technology for the delivery of poorly water-soluble drugs. Pharm Tech 2006; 30: 82-92.
34. Kesisoglou F, Panmai S, Wu Y. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007; 59: 631-644.
35. Crisp MT, Tucker CJ, Rogers TL, Williams III RO, Johnston KP. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J Control Release 2007; 117: 351-359.
36. Kesisoglou F, Panmai S, Wu YH. Application of nanoparticles in oral delivery of immediate release formulations. Curr Nanosci 2007; 3: 183-190.
37. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersion. Eur J Pharm Biopharm 2000; 50: 47-60.
38. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54: 631-651.
39. Dressman JB, Reppas C. In vitro-in vivo correlation for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000; 11: S73-S80.
40. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999; 88: 1058-1066.
41. Cavalli R, Gasco MR, Barresi AA, Rovero G. Evaporative drying of aqueous dispersions of solid lipid nanoparticles. Drug Dev Ind Pharm 2001; 27: 919-924.
42. Hoffart V, Ubrich N, Simonin C, et al. Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics. Drug Dev Ind Pharm 2002; 28: 1091-1099.
43. Rambali B, Verreck G, Baert L, Massart DL. Itraconazole formulation studies of the meltextrusion process with mixture design. Drug Dev Ind Pharm 2003; 29: 641-652.
44. Santhi K, Dhanaraj SA, Rajendran SD, Raja K, Ponnusankar S, Suresh B. Nonliposomal approach - a study of preparation of egg albumin nanospheres containing amphotericin-B. Drug Dev Ind Pharm 1999; 25: 547-551.
45. Cherian AK, Rana AC, Jain SK. Self assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug Dev Ind Pharm 2000; 26: 459-463.
46. Rojanapanthu P, Sarisuta N, Chaturon K, Kraisintu K. Physicochemical properties of amphotericin b liposomes prepared by reverse phase evaporation method. Drug Dev Ind Pharm 2003; 29: 31-37.
47. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34: 221-233.
48. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev 2001; 47: 65-81.
49. Koziara JM, Lockman PR, Allen DD, Mumper RJ. In-situ blood-brain barrier transport of nanoparticles. Pharm Res 2003; 20: 1772-1778.
50. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nano-particulate systems for peptide drug delivery. Adv Drug Del Rev 2001; 47: 39-54.
51. Loper A. Poorly soluble compounds: vehicle selection and solubilization. In: Land O'Lakes Conference: Drug metabolism and pharmacokinetics. 1999.
52. Kondo N, Iwao T, Masuda H, et al. Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region. Chem Pharm Bull 1993; 41: 737-740.
53. Wu Y, Loper A, Landis E, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004: 285: 135-146.
54. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 13: 155-168.
55. Liversidge GG, Conzentino P. Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995; 125: 309-313.
56. Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006; 111: 56-64.
57. Liversidge G, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125: 91-97.
58. Kayser O. A new approach for targeting Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int J Pharm 2001; 214: 83-85.
59. Müller RH, Kayser O, Jacobs C. Nanosuspensions for the formulation of poorly soluble drugs - rationale for development and what we can expect for the future. In: Nielloud F, Marti-Mestres G. (Eds.), Pharmaceutical emulsions and suspensions. Plenum Press/Marcel Dekker, New York 2000; pp. 383-408].
60. Na GC, Stevens Jr. J, Yuan BO, Rajagopalan N. Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm Res 1999; 16: 569-574.
61. Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006; 64: 360-368.
62. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254: 73-75.
63. Gupta RB. Fundamentals of drug nanoparticles. In Gupta RB, Kompella UB (Eds.), Nanoparticle technology for drug delivery, Taylor & Francis, NY 2006; pp. 3-4.
64. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55: 329.
65. Labhasetwar V. Nanoparticles for drug delivery. Pharm News 1997; 4: 28-31.
66. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Edn 2007; 8: 241-268.
67. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res 2006; 23: 1-30.
68. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-360.
69. Kono K, Arshady R (Eds.), Smart nanoparticles in nanomedicine (The MML series) Kentus Books, London 2006; v 8.
70. Bourgeat-Lami E, Lang JJ. Encapsulation of inorganic particles by dispersion polymerization in polar media: 1. silica nanoparticles encapsulated by polystyrene. J Colloid Interface Sci 1998; 197: 293-308.
71. Porter CJH, Charman WN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 2001; 50: S127-S147.
72. Jeong SH, Park JH, Park K. In: Wasan KM ed., Role of lipid excipients in modifying oral and parenteral drug delivery. John Wiley & Sons, Inc., Hoboken, New Jersey 2007; 32-47.
73. Porter CJH, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001; 50: 61-80.
74. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotech 2004; 113: 151-170.
75. Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Dev 2002; 5: 59-71.
76. Theis JG, Liau-Chu M, Chan H S, Doyle J, Greenberg ML, Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of cremophor EL. J Clin Oncol 1995; 13: 2508-2516.
77. O'Dwyer PJ, Weiss RB. Hypersensitivity reactions induced by etoposide. Cancer Res 1984; 68: 959-961.
78. Duma RJ, Akers MJ, Turco SJ. In: Avis KE, Lieberman HA, Lachman L (Eds.), Pharmaceutical Dosage Forms: Parenteral Medications 2nd edn, Marcel Dekker, New York, 1992; Vol. 1: 17-58.
79. Ward GH, Yalkowsky SH. Studies in Phlebitis. VI. Dilution-induced precipitation of amiodarone HCl. J Parenter Sci Technol 1993; 47: 161-165.
80. Davio SR, McShane MM, Kakuk TJ, Zaya RM, Cole SL. Precipitation of the renin inhibitor ditekiren upon iv infusion; in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey. Pharm Res 1991; 8: 80-83.
81. Merisko-Liversidge E, Sarpotdar P, Bruno J, et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996; 13: 272-278.
82. Boedeker BH, Logeski E, Kline M, Haynes D. Ultra-long duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals. J Clin Pharmacol 1994; 34: 699-702.
83. Peters K, Leitzke S, Diederichs JE, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chem 2000; 45: 77-83.
84. Karan SM, Lojeski EW, Haynes DH, et al. Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. Anesth Analg 1996; 82: 796-802.
85. Shulman M. Treatment of cancer pain with epidural butylamino benzoate suspension. Reg Anesth 1987; 12: 1-4.
86. Juliano RL. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv Drug Deliv Rev 1988; 2: 31-54.
87. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995; 16: 195-214.
88. Neal JC, Stolnik S, Garnett MC, Davis SS, Illum L. Modification of copolymers poloxamer 407 and poloxamine 908 can affect the physical and biological properties of surface modified nanospheres. Pharm Res 1998; 15: 318-324.
89. Liu Y, Bacon ER, Ballinger K, et al. Pharmacokinetic and hepatic disposition of Bis[1-ethoxycarbonyl)propyl]5-acetylamino-2,3,6- triiodoisophthalate in rats and isolated perfused rat livers. Drug Metab Dispos 2000; 28: 731-736.
90. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283-318.
91. Muller RH. Colloidal Carriers for Controlled Drug Delivery and Targeting, Modification, Characterization and in vivo Distribution. CRC Press, Boca Raton, FL, 1991.
92. Arshady R. Smart nanoparticles and nanotechnology. In K Kono and R Arshady (Eds.), Smart nano and microparticles (The MML series) Kentus Books, London 2006; v. 7: pp. 14.
93. Ballauff M, Lu Y. "Smart" nanoparticles: Preparation, characterization and applications. Polymer 2007; 48: 1815-1823.
94. Moghimi SM, Hunter ACH, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharm Rev 2001; 53: 283-318.
95. Curtis ASG, Wilkinson C. Nanotechniques and approaches in biotechnology. Trends Biotech 2001; 19: 97-101.
96. Wilkinson JM. Nanotechnology applications in medicine. Med Device Technol 2003; 14(5): 29-31.
97. Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomedicine 2006; 1 (2): 157-168.
98. Xu C, Sun S. Monodisperse magnetic nanoparticles for biomedical applications. Polym Int 2007; 56: 821-826.
99. Goodwin S, Peterson C, Hoh C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. J Magn Magn Mater 1999; 194: 132-139.
100. Vyas SP, Malaiya A. In vivo characterization of indomethacin magnetic polymethyl methacrylate nanoparticles. J Microencapsul 1989; 6(4): 493-499.
101. Lubbe AS, Bergemann C, Brock J, McClure DG. Physiological aspects in magnetic drug targeting. J Magn Magn Mater 1999; 194: 149-155.
102. Neuberger T, Schopf B, Hofmann H, Hofmann M, von Rechenberg B. Supermagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater 2005; 293: 483-496.
103. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021.
104. 4 particles by precipitation in the presence of PVA at high pH. J Col Inter Sci 1996; 177: 490-494.
105. Feltin N, Pileni MP. New technique for synthesizing iron ferrite magnetic nanosized particles. Langmuir 1997; 13: 3927-3933.
106. Fievet F, Lagier JP, Blin B, Beaudoin B, Figlard M. Homogeneous and heterogeneous nucleations in the polyol process for the preparation of micron and submicron size metal particles. Solid State Ionics 1989; 32-33: 198-205.
107. Sun S, Zeng H. Size-controlled synthesis of magnetite nanoparticles. J Am Chem Soc 2002; 124: 8204-8205.
108. Carreno TG, Mifsud A, Serna CJ, Palacios JM. Preparation of homogeneous Zn/Co mixed oxides by spray pyrolysis. Mater Chem Phys 1991; 27: 287-296.
109. 3 ultrafine powders by laser pyrolisis. Mat Lett 1998; 35: 227-231.
110. Miller E, Peppas NA, Winslow DN. Morphological changes of ethylene/vinyl acetate based on controlled delivery systems during release of water-soluble solutes. J Memb Sci 1983; 14: 79-92.
111. Zhao X, Harris JM. Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein. J Pharm Sci 1998; 87: 1450-1458.
112. Ruiz JM, Benoit JP. In vivo peptide release from poly(lactic-coglycolic acid) copolymer 50/50 microspheres. J Control Release 1991; 16: 177-186.
113. Li JK, Wang N, Wu XE. A novel biodegradable system based on gelatin nanoparticles and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery. J Pharm Sci 1997; 86(8): 891-895.
114. Akiyoshi K, Sunmoto J. Supramolecular assembly of hydrophobized polysaccharides. Supramol Sci 1996; 3: 157-63.
115. Jeong Y, Nah J-W, Na K, Cho CS, Kim SH. Self assembling nanospheres of hydrophobized pullulans in water. Drug Dev Ind Pharm 1999; 25: 917-927.
116. Schwick HG, Heide K. Immunochemistry and immunology of collagen and gelatin. Bibliotheca Haematol 1969; 3: 111-25.
117. Mehta RV, Upadhyay RV, Charles SW, Ramchand CN. Direct binding of protein to magnetic particles. Biotechnol Tech 1997; 11: 493-496.
118. Koneracka M, Kopcansky P, Antalik M, et al. Immobilization of proteins and enzymes to fine magnetic particles. J Magn Magn mater 1999; 201: 427-430.
119. Zavisova V, Koneracka M, Strbak O, et al. Encapsulation of indomethacin in magnetic biodegradable polymer nanoparticles. J Magn Magn Mater 2007; 311: 379-382.
120. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin -total remission in Yoshida sarcoma-bearing rats. Eur J Can Clin Oncol 1983; 19: 135-139.
121. Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target 1999; 6: 215-228.
122. Pulfer SK, Ciccotto SL, Gallo JM. Distribution of small magnetic particles in brain tumor-bearing rats. J Neuro Oncol 1999; 41: 99-105.
123. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery of anticancer drugs with intravenously administrated magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol 2000; 17: 309-316.
124. Tubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 2001; 18: 121-5.
125. Yang J, Lee CH, Park J, et al. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem 2007; 17: 2695-2699.
126. Luderer AA, Borrelli NF, Panzarino JN, et al. Glass-ceramic-mediated, magnetic- field-induced localized hyperthermia: response of a murine mammary carcinoma. Radiat Res 1983; 94: 190-198.
127. Chan DCF, Kirpotin DB, Bunn Jr PA. Synthesis and evaluation of colloidal magnetic iron oxides for the site specific radiofrequency-induced hyperthermia of cancer. J Magn Magn Mater 1993; 122: 374-378.
128. Hafeli UO, Pauer GJ. In vitro and in vivo toxicity of magnetic microspheres. J Mag Mag Mater 1999; 194: 76-82.
129. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm 2006; 62: 3-16.
130. Gassmann List PM, Schweitzer A, Sucker H. Hydrosols - alternatives for the parenteral application of poorly water soluble drugs. Eur J Pharm Biopharm 1994; 40: 64-72.
131. Kipp JE, Wong JCT, Doty MJ, Rebbeck CL. Microprecipitation Method For Preparing Submicron Suspensions, United States Patent 6,607,784, Baxter International Inc. (Deerfield, IL), USA, 2003, (14).
132. Rogers TL, Gillespie IB, Hitt JE, et al. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm Res 2004; 21: 2048-2057.
133. Rasenack N, Müller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res 2002; 19: 1894-1900.
134. Bilati U, Allemann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharmacol Sci 2005; 24: 67-75.
135. Ruch F, Matijevic E. Preparation of micrometer size Budesonide particles by precipitation. J Colloid Interface Sci 2000; 229: 207-211.
136. Sarkari M, Brown J, Chen X, Swinnea S, WilliamsIII RO, Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm 2002; 243: 17-31.
137. Zhang JY, Shen ZG, Zhong J, et al. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 2006; 323: 153-160.
138. Matteucci ME, Hotze MA, Johnston KP, Williams III RO. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 2006; 22: 8951-8959.
139. Chen JF, Zhang JY, Shen ZG, Zhong J, Yun J. Preparation and characterization of amorphous cefuroxime axetil drug nanoparticles with novel technology: high-gravity antisolvent precipitation. Ind Eng Chem Res 2006; 45: 8723-8727.
140. Parrott EL. In: Swarbrick J, Boylan JC, Eds, Comminution. Encyclopedia of Pharmaceutical Technology, Marcel Decker Inc, New York. 1990; 3: 101-121.
141. Chung HY, Yonemochi E, Saitoh T, et al. Factors affecting the apparent solubility of ursodeoxycholic acid in the grinding process. Int J Pharm 2003; 255: 49-56.
142. Yonemochi E, Oda K, Saeki S, Oguchi T, Nakai Y, Yamamoto K. Physicochemical properties of amorphous ursodeoxycholic acid obtained by grinding. Chem Pharm Bull 1994; 42: 1948-1950.
143. Yamamoto K, Nakano M, Arita T, Nakai Y. Dissolution rate and bioavailabity of griseofulvin from a ground mixture with microcrystalline cellulose. J Pharmacokinet Biopharm 1974; 2: 487-493.
144. Yamamoto K, Nakano M, Arita T, Takayama Y, Nakai Y. Dissolution behaviour of phenytoin from a ground mixture with microcrystalline cellulose. J Pharm Sci 1976; 65: 1484-1488.
145. Choi WS, Kim HI, Kwak SS, et al. Amorphous ultrafine particle preparation for improvement of bioavailability of insoluble drugs: grinding characteristics of fine grinding mills. Int J Miner Process 2004; 74S: S165-S172.
146. Vogt M, Kunath K, Dressman JB. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur J Pharm Biopharm 2007; In Press.
147. Merisko-Liversidge E, Cundy KC, Bishop JF, Czekai DA. Surface modified drug nanoparticles. US patent 5145684, 1992.
148. Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in Rats. Int J Pharm 1995; 125: 309-313.
149. Merisko-Liversidge E, McGurk S, Liverside GG. Insulin nanoparticles: A novel formulation approach for poorly water soluble Zn-Insulin. Pharm Res 2004; 21: 1545-1553.
150. Liverside GG, Cundy KC, Bishop JF, Czekai DA. Surface modified drug nanoparticles, US patent 5,145,684, 1992.
151. Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution 1999. US Patent 5858410.
152. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future? Adv Drug Deliv Rev 2001; 47: 3-19.
153. Zhang D, Tan T, Gao L, Zhao W, Wang P. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 2007; 33: 569-575.
154. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 2005; 299: 167-177.
155. Kumar MP, Rao YM, Apte S. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr Nanosci 2007; 3: 191-194.
156. Grau MJ, Muller RH. Increase of dissolution velocity and solubility of poorly soluble drugs by formulation as nanosuspension, in: Proceedings 2nd world Meeting APGI/APV, Paris, 1998, pp. 623-624.
157. Friberg SE, Quencer LG, Hilton ML. Theory of emulsions. In: Lieberman HA, Rieger MM, Banker GS. (eds), Pharmaceutical Dosage Forms, New York, Marcel Dekker, Inc., 1996; 53-90.
158. Hellweg T. Phase structures of microemulsions. Curr Opin Colloid Interface Sci 2001; 7: 50-56.
159. Lopez-Quintela MA. Synthesis of nanomaterials in microemulsions: formation mechanisms and growth control. Curr Opin Colloid Interface Sci 2003; 8: 137-144.
160. Gasco MR. Microemulsions in the pharmaceutical field: perspectives and applications In: Industrial Applications of Microemulsions. Marcel Dekker Inc., New York 1997; 97-122.
161. Debuigne F, Cuisenaire J, Jeunieau L, Masereel B, Nagy JB. Synthesis of nimesulide nanoparticles in the microemulsion epikuron/Isopropyl myristate/water/n-butanol (or isopropanol). J Colloid Interface Sci 2001; 243: 90-101.
162. Constantinides PP, Lambert KJ, Tustian AK, et al. Formulation development and antitumor activity of a filter-sterilizable emulsion of a paclitaxel. Pharm Res 2000; 17: 175-182.
163. Cilek A, Celebi N, Tirnaksiz F. Lecithin-based microemulsion of a peptide for oral administration: preparation, characterization, and physical stability of the formulation. Drug Deliv 2006; 13: 19-24.
164. Totta M, Gallarate M, Carlotti ME, Morel S. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int J Pharm 2003; 254: 235-242.
165. Tan HS, Borsadia S. Particle formation using supercritical fluids: pharmaceutical applications. Expert Opin Ther Pat 2001; 11: 861.
166. Shariati A, Peters CJ. Recent developments in particle design using supercritical fluids. Curr Opin Solid State Mat Sci 2003; 7: 371-383.
167. Yeo SD, Lim G, Debenedetti PG, Bernstein H. Formulation of microparticulate protein powders using a supercritical fluid antisolvent. Biotechnol Bioeng 1993; 41: 341-346.
168. Reverchon E, Della Porta G. Production of antibiotic micro- and nano-particles by supercritical antisolvent precipitation. Powder Technol 1999; 106: 23-29.
169. Reverchon E, Della Porta G, Falivene MG. Process parameters and morphology in amoxicillin micro and submicro particles generation by supercritical antisolvent precipitation. J Supercrit Fluids 2000; 17: 239-248.
170. Reverchon E, Marco ID, Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation. Int J Pharm 2002; 243: 83-91.
171. Chattopadhyay P, Gupta RB. Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer. Int J Pharm 2001; 228: 19-31.
172. Chattopadhyay P, Gupta RB. Protein nanoparticles formation by supercritical antisolvent with enhanced mass transfer. AIChE J 2002; 48: 235-243.
173. Hu J, Johnston KP, Williams III RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 2004; 30: 233-245.
174. Hu J, Johnston KP, Williams III RO. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci 2003; 20: 295-303.
175. Overhoff KA, Johnston KP, Williams RO. Improvement of dissolution rate of poorly water soluble drugs using a new particle engineering process: Spray freezing into liquid. ACS Symposium Series 2006; 924: 305-319.
176. Rogers TL, Johnston KP, Williams III RO. A comprehensive review: Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid COB2B and cryogenic spray-freezing technologies. Drug Dev Ind Pharm 2001; 27: 1003-1015.
177. Rogers TL, Hu J, Yu Z, Johnston KP, Williams III RO. A novel particle engineering technology: spray-freezing into liquid. Int J Pharm 2002; 242: 93-100.
178. Rogers TL, Nelsen AC, Sarkari M, Young T, Johnston KP, Williams III RO. Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: Spray-Freezing into Liquid with Atmospheric Freeze-Drying. Pharm Res 2003; 20: 485-493.
179. Rogers TL, Nelsen AC, Hu J. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur J Pharm Biopharm 2002; 54: 271-280.
180. Yu Z, Rogers TL, Hu J, Johnston KP, Williams III RO. Preparation and characterization of microparticles containing peptide produced by novel process: Spray Freezing into Liquid. Eur J Pharm Biopharm 2002; 54: 221-228.
181. Hu J, Johnston KP, Williams III RO. Rapid dissolving high potency danazol powders produced by spray freezing into liquid process. Int J Pharm 2004; 271: 145-154.
182. Williams III RO, Johnston KP, Young TJ, et al. Process for production of nanoparticles and microparticles by spray freezing into liquid. United States Patent 6862890, US Patent Issued on March 8, 2005.
183. Stahl K, Claesson M, Lilliehorn P, Linden H, Backstrom K. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm 2002; 233; 227-237.
184. Robert P, Carlsson RM, Romero N, Masson L. Stability of spray-dried encapsulated carotenoid pigments from Rosa Mosqueta (Rosa rubiginosa) oleoresin. J Am Oil Chem Soc 2003; 80:1115-1120.
185. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm 2005; 293: 155-164.
186. Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot JL, Leverge R. Spray -dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Biopharm 2003; 19: 273-280.
187. Re M-I. Formulating drug delivery systems by spray drying. Dry Technol 2006; 24: 433-446.
188. Wan LSC, Heng PWS, Chia CGH. Spray drying as a process of microencapsulation and the effect of different coating polymers. Drug Dev Ind Pharm 1992; 18: 997-1011.
189. Kawashima Y, Saito M, Takenaka H. Improvement of solubility and dissolution rate of poorly water-soluble salicyclic acid by a spray drying technique. J Pharm Pharmacol 1975; 27: 1-5.
190. Anhydro A/S. PSD 52 operating manual, Anhydro A/S, Soeborg, Denmark 2004.
191. Beppu B, Ozeki T, Sasaki Y, et al. Preparation of particles for dry powder inhalation using a novel 4-fluid nozzle spray drier. J Pharm Sci Technol Jpn 2003; 63: 228-237.
192. Gibson SG. How to optimize your spray dryer's performance. Powder Bulk Eng 2001; 4: 31-53.
193. Maa YF, Constantino HR, Nguten PA, Hsu CC. The effect of operating and formulation variables on the morphology of spray dried protein particles. Pharm Dev Tech 1997; 2: 213-223.
194. Allen RM, Bakker HHC. Spray dryer control based on-line particle size analysis. Transactions of IChemE: part A-Chem Eng Resear Design 1994; 72: 251-254.
195. Furuta T, Hayashi H, Ohashis T. Some criteria of spray drying design for food liquid. Dry Tech 1994; 12: 151-177.
196. Masters K. Spray Drying handbook. Halsted Press, New York, 1985.
197. Oakley DE. Produce uniform particles by spray drying. Chem Eng Prog 1997; 93: 48-54.
198. Alamilla-Beltran L, Chanona-Perez JJ, Jimenez-Aparicio AR, Gutierrez-Lopez GF. Description of morphological changes of particles along spray drying. J Food Eng 2005; 67: 179-184.
199. Broadhead J, Rouan SKE, Hau I, Rhodes CT. The effect of process and formulation variables on the properties of spray dried β-galactosidase. J Pharm Pharmacol 1994; 46: 458-467.
200. Sahoo NG, Abbas A, Zaher J, Li CM, Yuen KH. Preparation of an anti-malarial drug powder with enhanced solubility using a modified 4-fluid nozzle pilot spray drier" In preparation.
201. Hsu CC, Wu SS, Walsh AJ. The preparation of recombinant human deoxyribonuclease powder: comparative studies of spray drying versus lyophilization and application of microwave drying. Proceedings from the 10th International Drying Symposium (IDS'96). 1996; Vol. B: 1229-1236.
202. Blanco MD, Bernardo MV, Sastre RL, Olmo R, Muniz E, Teijon JM. Preparation of bupivacaine-loaded poly((-̇caprolactone) microspheres by spray drying: drug release studies and biocompatibility. Eur J Pharm Biopharm 2003; 55: 229-236.
203. Ermis D, Yuksel A. Preparation of spray-dried microspheres of indomethacin and examination of the effects of coating on dissolution rates. J Microencapsul 1999; 16: 315-324.
204. Giunchedi P, Maggi L, Torre ML, Conte U. Spray dried albumin microspheres containing carbamazepine. Proceed Intern Symp Control Rel Bioact Mater 1994; 21: 622-623.
205. Corrigan OI, Holohan EM, Sabra K. Amorphous forms of thiazide diuretics prepared by spray-drying. Int J Pharm 1984; 18: 195-200.
206. Corrigan OI, Holohan EM, Reilly MR. Physicochemical properties of indomethacin and related compounds co-spray dried with polyvinylpyrrolidone. Drug Dev Ind Pharm 1985; 11: 677-695.
207. Corrigan DO, Healy AM, Corrigan OI. The effect of spray drying solutions of polyethylene glycol (PEG) and lactose/PEG on their physicochemical properties. Int J Pharm 2002; 235: 193-205.
208. Takahashi H, Chen R, Okamoto H, Danjo K. Acetaminophen particle design using chitosan and a spray-drying technique. Chem Pharm Bull 2005; 53: 37-41.
209. Corrigan DO, Corrigan OI, Healy AM. Predicting the physical state of spray dried composites: salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems. Int J Pharm 2004; 273: 171-182.
210. Cerchiara T, Luppi B, Bigucci F, Zecchi V. Effect of chitosan on progesterone release from hydroxypropyl-b-cyclodextrin complexes. Int J Pharm 2003; 258: 209-215.
211. Koester LS, Xavier CR, Mayorga P, Bassani VL. Influence of β-cyclodextrin complexation on carbamazepine release from hydroxypropyl methylcellulose matrix tablets. Eur J Pharm Biopharm 2003; 55: 85-91.
212. Fernandes CM, Vieira MT, Veiga FJB. Physicochemical characterization and in vitro dissolution behavior of nicardipinecyclodextrinsinclusion compounds. Eur J Pharm Sci 2002; 15: 79-88.
213. Takeuchi H, Sasaki H, Niwa T, et al. Redispersible dry emulsion system as novel oral dosage form of oily drugs: in vivo studies in beagle dogs. Chem Pharm Bull 1991; 39: 3362-3364.
214. Hansena T, Holmc P, Rohded M, Schultza K. In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs. Int J Pharm 2005; 293: 203-211.
215. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yussa H, Okada H. Preparation of two-drug composite microparticles to improve the dissolution of insoluble drug in water for use with a 4-fluid nozzle spray drier. J Control Release 2005; 107: 387-394.
216. Sahoo NG, Abbas A, Zaher J, Li CM, Yuen KH. Solubility enhancement of a poorly water-soluble anti-malarial drug: Experimental design and use of a modified multi-fluid nozzle pilot spray drier. Revised to J Pharm Sci, In press.
217. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H. Preparation of polymeric submicron particle-containing microparticles using a 4-fluid nozzle spray drier. Pharm Res 2006; 23: 177-183.